- 1 Optimizing antibiotic use in Indonesia: a systematic review and synthesis of current
- 2 evidence to inform opportunities for intervention
- 4 Authors

3

7

18

- 5 Ralalicia Limato^{1,2}, Gilbert Lazarus^{1,3}, Puck Dernison^{1,4}, Manzilina Mudia¹, Monik Alamanda¹, Erni
- 6 J. Nelwan^{3,5}, Robert Sinto^{3,5}, Anis Karuniawati^{3,6}, H. Rogier van Doorn,^{2,7}, Raph L. Hamers^{1,2*}
- 8 Affiliations
- 9 1. Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
- 10 2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
- 11 Oxford, Oxford, UK
- 12 3. Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
- 4. Faculty of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
- 14 5. Department of Internal Medicine, Division of Infectious Diseases, Cipto Mangunkusumo
- 15 National General Hospital, Jakarta, Indonesia
- 16 6. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
- 17 7. Oxford University Clinical Research Unit, Hanoi, Vietnam
- 19 * Corresponding author
- 20 Raph L. Hamers MD PhD
- 21 Email: raph.hamers@ndm.ox.ac.uk
- 22 Phone: +62 21 31900971
- 23 Word count 4650; References 158; Inserts: Figures 4; Tables 2; Supplementary file: Figures
- 24 15; Tables 8
- 25 **PROSPERO registration number**: CRD42019134641

ABSTRACT

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

medication.

Introduction A major driver of antimicrobial resistance (AMR) and poor clinical outcomes is suboptimal antibiotic use, although data are lacking in low-resource settings. We reviewed studies on systemic antibiotic use (WHO ATC/DDD category J01) for human health in Indonesia, and synthesized available evidence to identify opportunities for intervention. Methods We systematically searched five international and national databases for eligible peerreviewed articles, in English and Indonesian, published between 1 January 2000 and 1 June 2021 including: 1) antibiotic consumption; 2) prescribing appropriateness; 3) antimicrobial stewardship (AMS); 4) perceptions among consumers and providers. Two independent reviewers included studies and extracted data. Study-level data were summarized using random-effects model metaanalysis for consumption and prescribing appropriateness, effect direction analysis for AMS interventions, and qualitative synthesis for perception surveys. (PROSPERO CRD42019134641) **Results** Of 9323 search hits, we included 100 reports on antibiotic consumption (20), prescribing appropriateness (49), AMS (13), and/or perception (25) (8 categorized in >1 domain). The pooled estimate of overall antibiotic consumption was 110.1 DDD/100 patient-days (95%Cl98.5-121.6), with ceftriaxone, ampicillin and levofloxacin being most consumed. Pooled estimates for overall appropriate prescribing (according to Gyssens method) were 33.5% (95%Cl18.1-53.4%) in hospitals and 49.4% (95%Cl23.7-75.4%) in primary care. Pooled estimates for appropriate prescribing (according to reference guidelines) were, in hospitals, 99.7% (95%Cl97.4-100%) for indication, 84.9% (95%Cl38.5-98.0%) for drug choice, and 6.1% (95%Cl0.2-63.2%) for overall appropriateness, and, in primary care, 98.9% (95%Cl60.9-100%) for indication, 82.6% (95%Cl50.5%-95.7%) for drug choice and 10.5% (95%Cl0.8-62.6%) for overall appropriateness. The few AMS intervention studies conducted to date suggested potential to reduce antibiotic consumption and improve prescribing appropriateness. Key themes identified in perception surveys were lack of antibiotic knowledge among consumers and non-prescription antibiotic self53 Conclusions Context-specific strategies are urgently needed to improve rational antibiotic use in

Indonesian hospitals and communities, with critical evidence gaps concerning private and informal

55 health providers.

54

56

57 **Key words:** antibiotic use; antibiotic consumption; antibiotic stewardship; Indonesia; systematic

58 review; meta-analysis

KEY QUESTIONS

59

60

61

70

80

What is already known?

- Indonesia is a potential AMR hotspot, where, based on pharmaceutical sales data, antibiotic
- consumption increased 2.5-fold between 2000 and 2015, mostly driven by broad-spectrum
- penicillins, fluoroquinolones and cephalosporins.
- Representative contemporary data on antibiotic use are lacking, although anecdotal data
- 66 suggest antibiotic overuse in the healthcare system, widespread over-the-counter use in
- 67 communities, and high rates of AMR mostly among common Gram-negative bacteria.
- A comprehensive review on antibiotic use in human health in Indonesia has not been
- 69 conducted to date.

What are the new findings?

- Available data spanning the past 20 years, suggested that only 34% and 49% of antibiotics
- were appropriately prescribed in hospital and primary care settings, respectively, although the
- 73 quality of the evidence was low.
- Publications evaluating AMS interventions have been sparse to date, demonstrating the need
- 75 to strengthen the local research base to develop context-specific and sustainable AMS
- 76 models.
- Community surveys suggested important gaps in antibiotic knowledge, and that non-
- 78 prescription antibiotic self-medication is common practice, although data to quantify this
- 79 problem and its drivers are lacking.

What do the new findings imply?

- Available evidence synthesised in this Review provides important insights in the magnitude
- 82 and patterns of antibiotic use, and associated patient and health system factors, which helps
- define opportunities for optimising responsible antibiotic use.
- Critical evidence gaps exist on informal and formal private health care providers, geographic
- 85 areas outside of Java Island, as well as effective AMS models that consider country-specific
- socio-cultural, economic and political circumstances.

- Optimization of antimicrobial use as a means to tackle AMR should be a priority of the national
- agenda for universal health coverage.

INTRODUCTION

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

The global rise in antimicrobial resistance (AMR) is considered one of the greatest public health threats worldwide, with a disproportionate impact in low- and middle-income countries (LMIC). A recent global analysis estimated that AMR was directly responsible for 1.27 million deaths and played a part in 4.95 million deaths in 2019. One of the major drivers of antimicrobial resistance (AMR) is antibiotic use, including their overuse and misuse, for human health.^{2,3} In low-resource settings, lack of access to quality health care, vaccination, safe water and sanitation, leave many people vulnerable to infection and dependent on antibiotics for treatment, with their use largely unregulated. At the same time, access to life-saving drugs targeting the emerging resistant pathogens remains an issue in many settings. Globally, during the past decade concerted efforts have been made to develop strategies to preserve the effectiveness of existing antibiotic agents. although this has been partially set back because of the COVID-19 pandemic.⁴ Indonesia is a lower-middle-income country in Southeast Asia with the world's fourth largest population (274 million), and socio-economic conditions and health indicators vary widely across the archipelago. More than 55% of the population is concentrated on Java Island, which contributes around 59% to the national economy and has the best developed health infrastructure. 5 Based on pharmaceutical sales data between 2000 and 2015, Indonesia ranks among the greatest risers in antibiotic consumption (29th of 76 countries).3 A range of complex factors, including variable access to quality health care, persistently high infectious disease burdens, and weakly enforced antibiotic policies, render Indonesia particularly vulnerable to AMR.⁵⁻⁷ The implementation of the National Action Plan for AMR, launched in 2017^{8,9} has been hindered due to, among other factors, a limited evidence base of AMR epidemiology, antibiotic utilisation and rational prescribing practices. We systematically reviewed the scientific literature on antibiotic use for human health, in both

hospital and primary care settings, in Indonesia spanning the past 20 years. This Review focused on four key domains: 1) antibiotic consumption; 2) appropriateness of antibiotic prescribing; 3)

- 118 AMS interventions; 4) knowledge, attitudes and perceptions among consumers and providers. This
- 119 Review also reflects on current progress in the National Action Plan for AMR, and defines
- evidence gaps and context-specific priorities for action.

METHODS

Search strategy and selection criteria

This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines. A detailed protocol has been prospectively registered in the PROSPERO database (CRD42019134641). Data for this systematic review were identified through the screening of five international (PubMed, EMBASE and Google Scholar) and national (Garuda [Garba Rujukan Digital] and Neliti) electronic bibliographic databases. Reference screening was used to identify additional relevant papers. The review was limited to antibacterials for systematic human use (J01 category in WHO ATC/DDD index). Only peer-reviewed original articles published in English or Indonesian between 1 January 2000 and 1 June 2021 were included. Search terms covered all domains of this Review and combined Indonesia, antibiotic, antimicrobial, consumption, prescription, dispensing and stewardship. Full search terms are listed in **Table S1**. We did not contact study authors.

We included original papers reporting on one or more of the following domains:

- 1. Antibiotic consumption: estimates of antibiotic utilization in adults expressed as defined daily dose (DDD) normalized to 100 patient-days (inpatients) or inhabitant-days (outpatients) (or with alternative units of measure that could be converted). DDD is defined as the assumed average maintenance drug dose per day for its main indication in adults as established by the WHO Collaborating Centre for Drug Statistics and Methodology. For this review, we extracted data on the top-15 antibiotics with the highest DDDs (defined as the top-3 antibiotics reported in at least two studies) and grouped them according to the WHO AwaRe (Access, Watch, and Reserve) classification.¹¹ We excluded paediatric studies because most studies incorrectly used DDD (not suitable for children) rather than days of therapy (DOT).
- 2. Appropriateness of antibiotic prescribing for treatment or prophylaxis: a) drug prescription audits using Gyssens method, 12,13 i.e., an expert panel (of at least two reviewers) retrospectively evaluates each antibiotic prescription (based on available clinical and microbiological data in the medical record and local guidelines) by sequentially categorizing six

indicators: (vi) insufficient data; (v) antibiotic is not indicated; (iv) alternative antibiotic is available that is (iv-a) more effective, (iv-b) less toxic, (iv-c) less costly, (iv-d) has narrower spectrum; (iii) inappropriate duration, (iii-a) either too long, (iii-b) or too short; incorrect (ii-a) dose, (ii-b) interval, (ii-c) route; (i) incorrect timing; and (0) appropriate use; b) studies that assessed antibiotic prescriptions according to named reference guideline(s), based on the following eight pre-defined indicators: no contra-indication or allergy label, indication, drug choice, dose, frequency, duration, route of administration, and overall rational use. We included in this category relevant indicators collected as part of point prevalence surveys (e.g., GLOBAL-PPS, WHO).

158

150

151

152

153

154

155

156

157

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

- 159 3. AMS interventions: intervention studies with a clearly described pre-post or (quasi-) 160 experimental design and outcome measures.
- 161 4. Knowledge, attitudes and perceptions (KAP): questionnaire-based surveys on knowledge, 162 attitude and/or practice of antibiotic use among consumers and/or providers.

We excluded non-human studies; studies exclusively describing other (non-J01) drugs; describing or comparing the effectiveness, cost, quality and/or molecular profiles of antibiotics; exclusively targeting particular diagnoses and its treatment; and studies of which the full text could not be accessed. Because the included studies were mostly neither randomised controlled studies nor comparative studies, traditional methods for assessment of risk of bias were not applicable. To ensure quality, we excluded studies that did not report an essential set of STROBE checklist core items, 14 or did not fulfil additional criteria (Table S2). All steps in this systematic literature search were conducted using Mendeley reference management software. Two reviewers (PD, MA) separately screened all titles and abstracts, and removed duplicates. Full-text articles were independently judged for relevance and quality by at least two reviewers (PD, MA, MM, RL). Any disagreements were resolved by a senior researcher (RLH).

Data analysis

We extracted and tabulated data on study design, location, population, health care setting, year of study, study sample size, indicators, interventions, outcome measures and effects, and emerging themes, as appropriate and relevant, based on the author-reported summary estimates (not individual patient-level data). Data were extracted by two reviewers (PD, MM) onto a predesigned form.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Where possible, data on antibiotic consumption and appropriateness of antibiotic prescribing were pooled using a random-effects model meta-analysis, due to the likeliness of unexplained heterogeneity. 15 Data on antibiotic consumption were pooled with meta-analyses of rates using the generic inverse variance method, with DDD/100 patient-days as the rate and sample sizes as the denominator. Data on the appropriateness of antibiotic prescribing, separate for Gyssens method and reference guidelines, were pooled with meta-analyses of proportions using the generalised linear mixed model (GLMM) with the logit transformation to retain studies with extreme proportions.¹⁶ Heterogeneity was assessed using I² statistic (low <25%, moderate 25-49%, substantial 50-74%, or high 75-100%) and chi-squared test (p<0.10). When two or more studies involved overlapping populations, data synthesis was prioritised to studies with larger sample sizes. Subgroup analyses were then performed by dichotomising the studies based on health care setting (primary care vs hospital [including secondary and tertiary levels]), study location (Java vs non-Java), year of study (before vs after 2016), AWaRe classification (access vs watch antibiotics) (for DDD only), and age groups (adults vs children) (for appropriateness only). To assess the robustness of the findings, we also performed a leave-one-out sensitivity analysis (for DDD and Gyssens), and by replicating the analysis using other transformations (i.e., Freeman-Tukey double arcsine, arcsine, inverse-variance logit, log transformations) and without transformation (for Gyssens only). All meta-analyses were performed in R version 4.1.0 using the additional meta (4.18-2), metafor (3.0-2), and forestplot packages (1.10.1). When appropriate (k≥10), publication bias assessments were performed visually by using funnel plots and quantitatively by using Egger's tests with a significance level set at 10%. The funnel plots were generated by plotting the inverse square root of study sizes against the effect estimates due to the expected variability of study sizes and the fact that conventional funnel plots may be inaccurate in assessing potential publication bias in meta-analyses of proportions. 17

Due to substantial clinical heterogeneity in studies evaluating AMS interventions, we synthesised the findings using a vote-counting method based on direction of effects, and subsequently summarised the results into an effect direction table. The interventions were classified as structural, enabling, persuasive, restrictive, or combined (bundled). Perception surveys were qualitatively synthesised based on the main emerging themes, stratified by consumers and providers.

Patient and public involvement statement

The patients and public were not involved in the development of this study.

RESULTS

Study characteristics

The search strategy collectively gave 9 323 hits. After title and abstract screening and duplicate removal, 551 articles remained (**Figure 1**). After full-text screening and quality assessment, 100 reports (covering 97 studies) were included. Study characteristics are summarized in **Tables 1** and **S3**. Most studies had an observational design (86.0%, 86/100), were conducted in the public sector (58.4%, 59/101), in hospital settings (53.0%, 53/100), in Java (60.2%, 62/103), and during the most recent five years (62.0%, 62/100).

Table 1. Characteristics of included reports

Total reports	N 100	%
Domains	107	
Antibiotic consumption	20	18.7
Appropriateness of antibiotic prescribing	49	45.8
Gyssens method	18	16.8
Reference guidelines	31	29.0
Antibiotic stewardship	13	12.1
Knowledge, attitude and practice survey	25	23.4
Study design	100	
Observational	86	86.0
Pre-post design	13	13.0
Randomized control trial	1	1.0
Study population	108	
Patients	74	68.6
Inpatients	56	51.9
Outpatients	18	16.7
Community	20	18.5
Healthcare providers	14	12.9
Study location	103	
Java	62	60.2
Sumatra	16	15.5
Papua and Nusa Tenggara	8	7.8
Sulawesi	7	6.8
Kalimantan	6	5.8
Bali	2	1.9
National	2	1.9
Year of study	100	
2016-2021	62	62.0
2011-2015	29	29.0
2000-2010	9	9.0
Healthcare level	100	
Primary	24	24.0
Hospital*	53	53.0

Total reports	N	%
Not applicable (community)	17	17.0
No information provided	6	6.0
Health care sector	101	
Public	59	58.4
Private	19	18.8
Not applicable (community)	19	18.8
No information provided	4	4.0

Total N for some characteristics are greater than N=100 because some reports were included in more than category, i.e.

Antibiotic consumption

A total of 20 reports (5 193 626 patients) reported data on antibiotic consumption.^{19–38} Most of the studies were conducted in hospital settings (16 reports, 76.2%), in Java (14 reports, 66.7%), and between 2016-2021 (17 reports, 81.0%; **Table S4**). The pooled estimate of overall antibiotic consumption was 110.1 DDD/100 patient-days (95% confidence interval [CI] 98.5-121.6; I²=100%; **Figure S1**), with ceftriaxone being the most consumed antibiotic (60.2 DDD/100 patient-days [95%CI 34.2-86.1]), followed by ampicillin (28.0 DDD/100 patient-days [95%CI 0.00-82.8]) and levofloxacin (21.4 DDD/100 patient-days [95%CI 15.4-27.3]; **Figure 3**). Sensitivity analysis found that the pooled estimate was not dominated by a single report (**Figure S2**).

Subgroup analyses (**Figure 3**) showed higher antibiotic consumption in hospitals (134.1 DDD/100 patient-days [95%CI 88.7-179.6]) than primary care (37.8 DDD/100 patient-days [95%CI 25.9-49.8]), and in recent years (2016-2021: 123.8 DDD/100 patient-days [95%CI 100.2-147.3]) than previous years (2000-2015: 55.2 DDD/100 patient-days [95%CI 18.5-91.9]), but there were no significant differences between Java (114 DDD/100 patient-days [95%CI 70.7-158.0]) and outside of Java (100.0 [95%CI 68.7-131.3]). The asymmetrical funnel plot (Egger's p=0.047; **Figure S3**) may indicate reporting bias or true heterogeneity in antibiotic consumption patterns between studies, hospitals and/or geographic areas.

Appropriateness of antibiotic prescribing

A total of 49 reports reported data on the appropriateness of antibiotic prescribing, of which 18^{33,39}

⁵⁵ (3167 prescriptions) used Gyssens method and 31 (7826 prescriptions)^{20,56–85} used reference

for domain (7 reports), population (8), location (3), and health care sector (1).

^{*} Hospital included secondary and tertiary levels.

guidelines. Most were conducted in hospitals (37 reports, 74.0%), in Java (33 reports, 66.0%), and in adults (29 reports, 58.0%) (**Table S5-S6**).

Based on the Gyssens method, the pooled estimate for the appropriateness of antibiotic prescribing was 35.3% (95%Cl 20.7-53.4%; l²=97.2%) (**Figure S4**). confidence analysis showed that the overall estimate was not dominated by a single study (**Figure S5**) and was similar between approximation methods (**Figure S6**). The symmetrical funnel plot (Egger's p=0.108; **Figure S7**) indicated low risk of bias from small-study effects. Subgroup analyses showed higher appropriateness of antibiotic prescribing in adults (43.1% [95%Cl 25.9-62.2%] than in children (8.4% [95%Cl 0.6-57.9%]), but there were no significant differences between primary care 49.4% [95% Cl 23.7-75.4%]) vs hospitals (32.3% [95%Cl 17.9-51.0%]), Java (31.4% [95%Cl 18.8-47.6%]) vs outside of Java (38.1% [95%Cl 6.2-85.0%], and recent years (2016-2021: 39.1% [95%Cl 19.4-63.0%] vs previous years (2000-2015: 26.1% [95%Cl 12.4-47.1%] (**Figure 4A**).

Based on reference guidelines, most individual indicators of appropriateness scored excellent (>80%), except for duration (65.8% [95%Cl 38.6-85.5%]) (**Figure 4B**) and overall rational antibiotic use (8.0% [95%Cl 1.0-43.6%]). Between-study heterogeneity was substantial (75-100%) for all indicators, except for administration route (l²=0%, p>0.999) and no contraindication/allergy label (l²=6.4%, p=0.382). Possible small-study effects were found for indication and duration (Egger's test p=0.092 and p=0.074, respectively). Subgroup analysis showed higher appropriateness of duration in hospitals (80.0% [95%Cl 66.0-89.2%]) than primary care (34.5% [95%Cl 4.3-86.1%]), and in adults (83.2% [95%Cl 65.3-92.9%] than children (17.9% [95%Cl 1.2-79.4%]; **Figure S8**), and higher appropriateness of drug choice, dosing, and overall rational use outside of Java (95.2% [95%Cl 73.9-99.3%], 90.0% [95%Cl 71.1-97.1%], and 34.5% [95%Cl 3.1-89.8%] than in Java (70.0% [95%Cl 23.2-94.7%], 67.2% [95%Cl 32.3-89.8%), and 3.3% [95%Cl 0.3-32.0%]; **Figure S9-S11**, respectively) –although the latter differences were not statistically significant. There were no significant differences for no contraindication/allergy label, indication, dosing frequency, or administration route (**Figure S12-15**).

Antibiotic stewardship interventions

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

A total of 13 reports reported data on the effect of AMS interventions, of which 11 in hospitals, ^{23,28,31,33,47,86-91} 1 in primary care, ⁹² and 1 in community pharmacies ⁹³ (**Table 2**). Twelve reports used a pre-post design, and one was a randomized controlled trial. Four reports evaluated a bundled intervention and 9 studies evaluated single interventions. Enabling interventions were most common (antibiotic prescribing guidelines or clinical pathway [8 reports], education and training [5] and pharmacist counselling [1]), followed by persuasive interventions (audit and performance feedback [3]), restrictive interventions (antibiotic restriction with pre-approval [1]) and structural interventions (free blood cultures [1], integrated drug management [1]). The most common reported outcome measures were changes in appropriateness of prescribing (10 reports), antibiotic consumption (8) and mortality (2), followed by prescribers' scores for knowledge of and attitude towards antibiotic use, blood culture sampling, hand hygiene compliance, clinical outcomes, length of hospital stay, and antibiotic compliance (1 each). Studies that evaluated bundled interventions (4 reports) reported favourable effects on antibiotic consumption, prescribing appropriateness, guideline compliance, blood culture sampling, HAI rates, hand hygiene compliance, and mortality, although the authors of one study concluded that the multifaceted intervention had limited success, with a very important drawback being the absence of adequate microbiological diagnostics. 31,88,89,92 Studies that evaluated the implementation of antibiotic prescribing guidelines or clinical pathway (7 reports) reported mixed effects on antibiotic consumption and favourable effects on prescribing appropriateness.^{23,31,47,86,88,90,91} Studies that evaluated education and/or training interventions (5 reports) reported mixed effects on antibiotic consumption and prescribing appropriateness. 31,87-89,92 The one study that evaluated antibiotic restriction with pre-approval found that consumption of restricted antibiotics decreased and of unrestricted narrow-spectrum antibiotics increased.²⁸ The one randomised study that evaluated the effect of a pharmacist counselling session of outpatient

- 311 antibiotic users in community pharmacies found that self-reported antibiotic adherence was
- 312 significantly higher in the intervention group compared to the control group.⁹³

Table 2. Summary of reports on antimicrobial stewardship interventions

Author	Year of study	Location (city, province)	Health care setting	Study population	Study design	Intervention description	Outcome measures	Summary of study findings	Effect direction	Favourability of effect	Comments	
Hadi (2008) ³¹	2003- 2004	Surabaya (East Java)	Tertiary hospital	Residents and specialists in the	Pre-post design	Combined: comprising guideline development,	Antibiotic consumption	Antibiotic consumption decreased from 99.8 to 73 (-26.9%) DDD/100 patient-days.	▼	(+)	The multifaceted intervention had	
			·	internal medicine department		distribution of a guideline pocketbook, free-of-charge blood cultures, teaching sessions and refresher	Appropriate antibiotic prescribing (Gyssens)	Appropriate antibiotic prescribing improved insignificantly from 16% to 25% overall (+9%, 95%CI -6% to 24%). Prescribing without indication insignificantly decreased from 53% to 40% (-13%, 95%CI 4% to -32%).	2	(+)	limited success, with a very important drawback being the absence of adequate	
						courses	Guideline compliance	Guideline compliance did not change overall (from 87% to 88%), except for a significant increase for sepsis (from 49% to 72%; +23% [95%Cl 4-41%]) and dengue fever (from 58% to 88%; +30% [95%Cl 12-48%]).	∢⊳	(+/-)	microbiological diagnostics.	
							Blood culture sample taken	Taking blood cultures increased from 3% to 81%. However, only 3% of the blood cultures post-intervention were taken before starting antibiotic treatment.	A	(+/-)		
							Mortality within 6 days of admission	Mortality in pre-post-period were similar (from 6.6% to 6.2%).	4 ▷	(+/-)		
Murni (2014) ⁸⁹	2011- 2013	Yogyakarta (Daerah Istimewa Yogyakarta)	Tertiary hospital	All doctors, nurses, and allied workers in the paediatric wards and PICU	nurses, and allied workers in the paediatric wards	Combined: comprising educational seminars, audit and performance feedback	Primary: Proportion of patients with an HAI	Proportion of patients with HAI decreased from 22.6% (277/1227 patients) to 8.6% (123/1419 patients) (RR 0.38 [95% CI 0.31 to 0.46]).	▼	(+)	Multifaceted intervention reduced HAI rates, improved rational	
							use (referen	Secondary: inappropriate antibiotic use (reference	Inappropriate antibiotic use decreased from 43% to 20.6% (RR 0.46 [95%CI 0.40 to 0.55]).	▼	(+)	use of antibiotics, increased hand hygiene
							guideline), hand hygiene compliance and mortality rates	Hand hygiene compliance improved from 18.9% (319/1690) to 62.9% (1125/1789) (RR 3.33 [95%CI 2.99 to 3.70]).	A	(+)	compliance, and reduced mortality in children	
											In-hospital mortality decreased from 10.4% (127/1227) to 8% (114/1419) (RR 0.78 [95%Cl 0.61 to 0.9]7).	▼
Hapsari (2006) ⁸⁸	2003- 2004	Semarang (Central	Tertiary hospital	Doctors in the paediatric ward	Pre-post design	Combined: comprising development of	Antibiotic consumption	Antibiotic consumption decreased from 0.48 to 0.38 DDD/100 patient-days (p=0.01).	▼	(+)		
. ,		Ĵava)	·			antibiotic prescribing guideline, prescriber training, and two rounds of feedback during a 6 months' period	Appropriate antibiotic prescribing (Gyssens)	Appropriate antibiotic prescribing improved from 37% to 70.4% (p<0.01). Prescribing without indication did not change (from 43% to 42.7%).	A	(+)		
Dwiprahasto (2004) ⁹²	1997- 1998	West Kalimantan, West Sumatra, West Nusa	Primary care	Doctors, nurses, and paramedics at 118 PHCs and provincial health office staff in 18	Pre-post design with control group	Combined: (1) Interactive problem- based pharmacotherapy training; (2) integrated	Proportion of patients with ARI who received an antibiotic	Significant decrease from 92.7-93.4% of patients to 64.6-72.4% after 6 months (p<0.05) and 35.4-37.4% after 12 months (p<0.01) post-interpretation, compared to no decline in the control group (89.9-92.2%)	•	(+)		
		Tenggara, East Java		districts' warehouses		drug management and use for provincial health office staff; followed by (3) self-monitoring of drug use at PHCs post-intervention, and monthly reporting to health office.	The use of injection medication (analgesic or antibiotic combined with antihistamine) for myalgia	Significant decrease from 82.4-89.2% of patients to 76.2-72.5% after 6 months (p<0.05) and 32.8-41.2% after 12 months (p<0.01) post-intervention, compared to no significant decline in the control group (86.2-87.2%)	•	(+)		

Author	Year of study	Location (city, province)	Health care setting	Study population	Study design	Intervention description	Outcome measures	Summary of study findings	Effect direction	Favourability of effect	Comments
King (2015) ⁹⁰	2015	Semarang (Central Java)	Tertiary hospital	Prescribers In the digestive surgery ward	Pre-post design	Enabling: Implementation of a revised antibiotic prescribing guideline	Proportion of patients who received an antibiotic	Proportion of patients who received an antibiotic insignificantly decreased from 50% to 40.7% for therapeutic use, and from 32.5% to 29.6% for surgical prophylaxis (overall pvalue = 0.410).	₫▷	(+/-)	
							Antibiotic consumption	Antibiotic consumption increased from 35.4 to 51.1 DDD/100 patient-days, mostly ceftriaxone and ciprofloxacin	2	(-)	_
Rosdiana (2017) ⁴⁷	2016	Pekanbaru (Riau)	Secondary hospital	Doctors in internal medicine ward	Pre-post design	Enabling: Development and	Appropriate antibiotic prescribing (Gyssens)	Appropriate antibiotic prescribing increased from 33.7% to 48.8% (p=0.020)	A	(+)	
(,		(*122)				implementation of antibiotic prescribing guideline	pressuming (e) each	Prescribing without indication decreased from 27.2% to 16.3% (p=0.038).	•	(+)	
Narulita (2020) ²³	2018- 2019	Pamekasan (East Java)	Secondary hospital	Prescribers in surgery wards	Pre-post design	Enabling: Implementation of an antibiotic prescribing guideline	Antibiotic consumption	Antibiotic consumption decreased from 197.3 to 102.4 DDD/100 patient-days (p=0.065)	▽	(+)	
Lizikri (2020) ⁹¹	2017- 2018	No city mentioned	Secondary hospital	Pediatricians at pediatric wards	Pre-post design	Enabling: Development and	Length of hospital stay (days)	Proportion of patients discharged <3 days decreased from 51.7% to 31.1% (p=0.065)	▽	(-)	The intervention could not achieve
		(West Java)				implementation of a pneumonia clinical pathway, with a patient management algorithm	Clinical outcomes (recovered, ICU/referred)	No discernible change in clinical outcomes as nearly all study patients had good clinical outcomes (p=1.00)	4⊅	(+/-)	the targeted goals to reduce the length of hospitalization and improve
							Appropriate antibiotic prescribing (Gyssens)	Appropriate antibiotic use did not change from 3.3% to 3.3% (p=1.00)	₫ Þ	(+/-)	antibiotic prescribing.
							Antibiotic consumption	Antibiotic consumption increased from 222.4 to 408.4 DDD/100 patient-days (p=0.408)	2	(-)	Consumption almost doubled.
Widowati (2018) ⁹³	2018	Denpasar (Bali)	Community pharmacy	Pharmacy clients purchasing antibiotics	Randomized controlled trial	Enabling: Intervention group: counseling by a pharmacist; Control group: drug information according to the pharmacy service standard.	Antibiotic compliance was measured using the Morisky Medication Adherence Scale-8 questionnaire within 3-5 days after purchasing the medication	The proportion of compliance in the intervention group was 65.3% and the control group was 18.4% (proportion ratio 3.56, 95% CI: 1.90- 6.64).	A	(+)	
Karuniawati (2021) ⁸⁶	2016- 2018	Surakarta (Central	Secondary hospital	Hospital-wide prescribers	Pre-post design	Enabling: Implementation of a	Antibiotic consumption	Antibiotic consumption decreased from 90.8 to 61.4 DDD/100 patient-days	▼	(+)	Shift from predominantly "red"
()		Java)		processing of		hospital antimicrobial stewardship	Appropriate antibiotic prescribing (Gyssens)	Appropriate antibiotic prescribing improved from 31.3% to 62.5%	A	(+)	antibiotics (mostly ceftriaxone) to
						programme for pneumonia inpatients	, , ,	Prescribing without indication did not change (from 0% to 0%)	4 ⊳	(+/-)	"green" antibiotics (mostly ampicillin
							Length of hospital stay (days)	Length of stay did not change significantly from 9.9 days to 10.0 days	4 ⊳	(+/-)	sulbactam)
Farida (2008) ⁸⁷	2003- 2004	Semarang (Central Java)	Tertiary hospital	Doctors in the pediatric ward	Pre-post design	Enabling: Prescriber training on appropriate antibiotic use (two-day training seminar) with	Prescribers' scores for knowledge of and attitude towards antibiotic use	Scores for knowledge of and attitude significantly increased from 59 to 77.5, and from 56 to 59, respectively.	A	(+)	
						feedback after one month	Appropriate antibiotic prescribing (Gyssens)	Appropriate antibiotic prescribing improved significantly from 36.3% to 58.2% (p<0.01) overall, except for pneumonia (decreased) and typhoid fever (no change). Prescribing without indication significantly decreased from 42.7% to 23.3% (p<0.05).	A	(+)	
Kartika (2019) ³³	2018	Semarang (Central Java)	Secondary hospital	Doctors, nurses, and pharmacists in internal medicine wards	Pre-post design	Enabling: Antimicrobial resistance & stewardship training	Antibiotic consumption	Antibiotic consumption decreased insignificantly from 103.7 to 99.6 DDD/100 patient-days (p =0.092)	▽	(+)	

Author	Year of study	Location (city, province)	Health care setting	Study population	Study design	Intervention description	Outcome measures	Summary of study findings	Effect direction	Favourability of effect	Comments
	2017- 2018	Pekanbaru (Riau)	Secondary hospital	Hospital-wide prescribers	Pre-post design	Restrictive: Implementation of a hospital-wide antibiotic restriction programme. Pre-approval was required from the antibiotic stewardship team for third-line	Antibiotic consumption for restricted and unrestricted antibiotics	Consumption decreased of restricted antibiotics meropenem (from 3.39 to 2.71; p=0.04); doripenem (from 0.42 to 0.08; p=0.003); imipenem (from 0.29 to 0.04; p=0.02); cefepime (from 1.53 to 0.28; p=0.001), whereas consumption of amikacin, tigecycline, vancomycin remained unchanged.	•	(+)	
						antibiotics		Consumption decreased of the unrestricted antibiotics ceftriaxone (from 14.8 to 9.4; p=0.03) and levofloxacin (from 13.6 to 9.0; p=0.02). Consumption increased of the narrow-spectrum antibiotics ampicillin/sulbactam (from 1.82 to 3.66; p=0.003) and cefazoline (from 1.38 to 4.38; p=0.001)	< ▷	(+/-)	

The table summarizes 13 reports in the domain antimicrobial stewardship interventions. Findings are synthesized based on direction and favourability of effects. Antibiotic consumption is expressed as DDD/100 patient-days.

318

Abbreviations: ARI, acute respiratory infection; CI, confidence interval; DDD, defined daily dose; HAI, hospital-associated infection; ICU, intensive care unit; PHCs, primary health care centres; PICU, paediatric intensive care unit; RR, relative risk

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

Knowledge, attitudes, and perceptions on antibiotic use among consumers and providers A total of 25 reports reported data on KAP, of which 22 among communities 94-115 and 3 among healthcare providers 116-118 (Table S7-S8). Interpretation was challenged by the considerable between-study clinical (e.g., study populations) and methodological (e.g., survey questionnaires) heterogeneity. First, there was a substantial lack of AMR awareness (10 reports) and knowledge about antibiotics (16) among community respondents, with wide variations between communities: overall, 23-26% did not know that antibiotic treated bacterial infections and 58-74% stated that antibiotics can cure viral infections. 96,105,110,115 Antibiotic knowledge was found to be associated with higher education and higher income (2 reports). 105,111 Second, antibiotic self-medication without prescription was reportedly common community respondents, ranging from 20-100% across studies (9 reports). Respondents reported they purchased antibiotics for self-medication at the pharmacy (46-90%), 94-96,99,104,106,109,112 at the kiosk (20-44%), 96,104 or received them from family and friends (9-12%), 95,109 20-100% of community respondents reported that they had ever self-medicated with an antibiotic (11).94- $_{96,99,102,104,106,109,112-114}$ and 87-100% had ever purchased an antibiotic without a prescription (3). 104,109,112 Higher education and higher income was correlated with better antibiotic use knowledge.111 One study found that people without health insurance were more likely to selfmedicate than those with health insurance. 111 whereas another study reported the opposite. 104 The main reasons for self-medication included positive previous experience (54-82%), 102,104,109,112 selfmedication being practical (61-83%), 94 easy access from the pharmacy (71%), 102 and doctor visit being expensive (44-72%)^{102,109} or unpractical (56%).⁹⁶ The main advisors to self-medicate included health care providers (51-83%), 100,103,104,109 family, relatives or friends (21-45%), 96,102,112 internet (71%), 115 or reliance on their own knowledge (71%). 96 Antibiotic adherence levels were not associated with education level or employment status (2 studies). 98,101

Third, antibiotic dispensing without prescription was the most important theme reported among health care providers, with conflicting findings. A survey among 250 community pharmacists in Yogyakarta (Java), 68% reported that they would dispense antibiotics without prescription, there as a survey among 110 health providers in community health centres in Padang (Sumatera) found that 98.8% did not prescribe antibiotics without a prescription, despite patient request.

DISCUSSION

This is the first comprehensive, systematic assessment of human antibiotic use in Indonesia, including 100 peer-reviewed reports spanning the past 20 years, covering the key domains of antibiotic consumption, prescribing appropriateness, AMS interventions, and perceptions among consumers and providers. The rising number of scientific reports published in the most recent years in Indonesia reflects the increasing momentum of AMR on the national health agenda. The evidence collected in this Review comes from a range of health care and community settings, including hospitals, primary care, pharmacies and communities, and includes a range of interventions targeting different types of health providers and consumers. Nonetheless, the evidence base is uneven with hospital and urban contexts over-represented, and informal and formal private health providers, who play a major role in antibiotic distribution, particularly underrepresented.

The data included in this Review highlighted several critical evidence gaps. First, there were important limitations in data heterogeneity and study methodology, and publications were predominantly from Java Island, which limited our ability to draw firm conclusions on the contemporary nationwide antibiotic use situation in Indonesia. This is especially relevant given the substantial within-country variations in access to quality health care.⁵ Representative, high-quality data will be essential for benchmarking between provinces, districts, and healthcare facilities, and internationally. Second, there is a lack of knowledge of health system drivers of community antibiotic use, including the effects of the national health insurance rolled-out since 2014, enforcement of antibiotic regulations in informal and private health sectors, as well as how to achieve effective community antibiotic stewardship. Antimicrobials are presently widely available without a prescription, despite existing restrictive policies.¹¹⁹ Third, the COVID-19 pandemic has suggested a widespread failure of AMS globally with the potential to worsen the AMR crisis.^{4,120} Data of its impact in the Indonesian context are urgently needed.

Antibiotic consumption

Across the included studies, ceftriaxone, levofloxacin (both Watch) and ampicillin (Access) were found to be the most consumed antibiotics among adults, and consumption (expressed as DDD) was higher in hospitals than in primary care, and in recent years (2016-2021) than previous years (2000-2015), but there were no significant differences between geographic settings. According to national pharmaceutical sales data, antibiotic consumption increased 2.5-fold between 2000 and 2015, largely driven by the major classes broad-spectrum penicillins (2.6-fold), fluoroquinolones (7.1-fold), and cephalosporins (5.1-fold). ¹²¹ In 2015, the antibiotic consumption rate per capita in Indonesia (3022 DDDs per 1000 inhabitants per year) fell in the same range as, for instance, China (3060) and Philippines (2600), but was still lower than, for instance, Vietnam (11 480), Thailand (6682) and Malaysia (4388). ¹²¹ About 69% of antibiotic consumption in Indonesia were Access antibiotics, 30% Watch, and <1% Reserve –this is still above the WHO target of 60% Access antibiotics in total consumption. ³

These trends reflect both better access to antibiotics for those who need them, as well as increases in inappropriate antibiotic use. The findings are consistent with the widespread use of broad-spectrum antibiotics, predominantly third-generation cephalosporins and fluoroquinolones, as reported in other Asian countries¹²²⁻¹²⁶ and globally,^{127,128} and with the disproportionate increase in Watch antibiotic consumption observed in LMIC (165% compared with 27.9% in high-income countries between 2000-2015).¹²⁹ Although antibiotic consumption per capita in Indonesia and many other LMIC is currently still lower than in most high-income countries in Europe and North America, rapid increases are leading to converging consumption rates, especially regarding last-resort compounds.³ Barring policy changes, antibiotic consumption is projected to increase worldwide by 200% between 2015 and 2030.³ The above concerning developments highlight significant challenges for AMS, underscoring the urgent need for regulation of antibiotic use in Indonesia, and other LMIC.

Appropriateness of prescribing

In Indonesia, appropriateness of antibiotic prescribing was found to be poor overall (35.3%), 49.4% in primary care versus 33.5% in hospitals, 45.9% in adults versus 8.4% in children. We did

not identify clear trends over time (prior vs after 2016) or space (Java vs outside of Java). This was despite nationwide implementation of hospital AMS programmes during the past five years.⁷ Studies in primary healthcare settings in other countries have also reported considerable rates of inappropriate antibiotic use, for instance, at 15% in Canada,¹³⁰ 55% in South Africa,¹³¹ 61% in China,¹³² 88% in Pakistan,¹³³ and 90% in Vietnam,¹³⁴ and, likewise, a systematic review of nine studies in LMIC reporting a wide range of between 8 to 100%.¹³⁵ In a global point prevalence survey, guideline compliance of antimicrobial drug choice in hospitals in Latin America, Africa and Asia, was estimated to be lower than 70% for each region.¹²⁷

Inappropriate prescribing of antibiotics has been attributed to a range of complex factors, with variations across settings and countries, including physicians' nonadherence to antibiotic guidelines, lack of knowledge and training regarding antibiotics, lack of diagnostic facilities or, where available, lack of utilization and quality, uncertainty over the diagnosis or fear of clinical failure, pressure from pharmaceutical industry, financial benefits for physicians, and pressure from patients to prescribe antibiotics regardless of the indication, coupled with lack of time of physicians to educate patients. 136,137 Around 60% of total health care spending in Indonesia is in the private sector, where financial incentives may promote prescribing practices that deviate from guidelines. The scale and consequences of non-prescription and private sector antibiotic consumption in Indonesia are an urgent priority for further study and action. Additionally, the local implementation of global definitions and universally applicable quality indicators for antibiotic prescribing in inpatient and outpatient settings will be essential to identify targets for AMS interventions and measure their effectiveness. 138,139 Standardized point prevalence survey tools to assess antibiotic use in hospitals have proven to be useful for identifying targets for improvement and evaluating the effect of interventions. 127,128

Antimicrobial stewardship

According to WHO, AMS is considered one of three pillars of an integrated approach to health systems strengthening and reports from high-income settings have shown that AMS can optimise the use of antimicrobials, improve patient outcomes, reduce AMR and health-care-associated

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

infections, and save health-care costs amongst others. 18,140 A global systematic review and metaanalysis of 26 studies, reported that implementation of AMS programmes resulted in a reduction in overall antibiotic consumption of 19.1% (US 19.9, Europe 20.9%, Asia 16%), of restricted antibiotics by 26.6%, reduction in drug resistant infections, with no associated adverse outcomes in terms of mortality and infection rates. 141 In Indonesia, AMS programmes are typically in an early stage of implementation, 142,143 with many hospitals lacking the basic infrastructure to adequately measure process, outcome and structural indicators, e.g., access to microbiology services, hospital antibiotic guidelines, AMS staff training and education, human resources (including infectious disease specialist or clinical microbiologist), and ICT support. 144,145 Whereas to date government policy has focused on assessing hospital antibiotic use as an AMS outcome indicator (using DDD and Gyssens method). 145 a recently launched national guideline incorporated additional outcome measures, such as costeffectiveness, mortality, and AMR rates. 146 The few AMS intervention studies conducted to date reported clear benefits from implementing bundled interventions combining antibiotic prescribing guidelines, trainings, review and feedback, restriction with pre-approval, among others. These findings demonstrate that AMS interventions are feasible in the local context and that there is considerable potential for reducing antibiotic consumption, particularly of restricted antibiotics, improving prescribing appropriateness, and reducing prescriptions without indication. However, the interventions evaluated to date were mostly single-centre and short-term (<1 year), and data are lacking about the sustained benefits of AMS programmes in the Indonesian context. Previous evidence has shown that given the varying priorities and contextual issues in LMIC, such as health system processes, patient demands, varying cultures of care, availability of universal access to quality antimicrobials, laboratory infrastructure and surveillance systems, multipronged interventions combining different restrictive and enabling strategies are most likely to be effective. 147,148 Indeed, the available Indonesian data confirm that a stand-alone guideline

distribution approach, without implementing additional AMS core elements, may not work.¹⁴⁹ Further enhancement of post-prescription review and feedback efforts holds potential to decrease antibiotic consumption and antibiotic duration.¹⁵⁰ For pre-prescription approval, local data suggested that the decreased use of last-resort antibiotics might cause a "squeezing the balloon" phenomenon –the increased use of non-restricted antibiotics due to restrictions of the restricted antibiotics.¹⁵¹

Perceptions on antibiotic use

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

Key themes identified from perception surveys were a substantial lack of AMR awareness and knowledge about antibiotics, particularly among the poor and lower educated, and widespread antibiotic self-medication without prescription among the general population, and over-the-counter non-prescription antibiotic dispensing in community pharmacies but not in community health centres -although representative data are lacking to quantify this problem and its drivers. The available data corroborate findings of a global review of 38 studies from 24 countries in community pharmacies that over-the-counter non-prescription antibiotics comprised 62% of all dispensed antibiotics, most commonly for urinary tract and upper respiratory tract infections. 152 A review of 19 studies in Southeast Asia reported a prevalence of self-medication with antibiotics ranging from 7.3 to 85.6% (median 42.6%), highest among men, health students and professionals, with the most common illnesses or symptoms being common cold, sore throat, fever, gastrointestinal tract and respiratory diseases.¹⁵³ Across the included studies, the main reasons for self-medication included positive previous experience, easy access from the pharmacy, doctor visit being expensive or unpractical, and the main advisors to self-medicate included health care providers, family, relatives or friends, internet or reliance on their own knowledge, which largely concurred with findings in other Southeast Asian countries. 153 A mixed-method study in Indonesia found that drug dispensers were driven to sell non-prescription antibiotic due to strong patient demand, informal drug sellers dispensing medicines, competition between different types of drug outlets, drug outlet owners pushing their staff to sell medicines, and weak enforcement of regulations. 119

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

The National Action Plan on AMR has driven efforts to strengthen microbiological laboratory capacity and data information systems to enable national surveillance, 154 supported by the government and international funding agencies. Indonesia enrolled in the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) and submitted first batches of AMR and antibiotic consumption data in 2020. 155 In 2021, the Ministry of Health launched new guidelines for antibiotic prescribing and stewardship, 146,156 which have also adopted the AWaRe classification. Despite this progress, however, the National Action Plan for AMR has not yet generated the required sustainable capacity to contain AMR. Enhanced coordination and financial support at the country, province and district levels are needed, to prevent that the response to AMR remains uneven and insufficient. Interventions to optimise antimicrobial use need to be based on a health systems approach, beyond AMS only, informed by a broad research base. This includes addressing the wider drivers of antibiotic use -such as inequitable burdens of ill health and fractured care cascades. Optimization of antimicrobial use, on the basis of robust surveillance data, should be a priority of the national agenda for universal health coverage. Both universal health coverage and AMR require strong human-centered care with accessible health care facilities, medicines and diagnostics, with a focus on quality and equity. 5,157,158 This requires further investments in health care infrastructure, training of health workers, community participation and increased health literacy. Modifiable factors related to the patient (e.g., awareness, knowledge) and the health system (e.g., strict policies, medicine quality, financial incentives, infrastructure gaps) need to be further identified and addressed when designing context-specific interventions aimed at curtailing inappropriate antibiotic use.

CONCLUSION

Critical evidence gaps exist on antibiotic use in Indonesia regarding informal and formal private health care providers, geographic areas outside of Java Island, as well as effective AMS models that consider country-specific socio-cultural, economic and political circumstances. Optimisation of antimicrobial use as a means to tackle AMR should be a priority of the national agenda for universal health coverage. In this respect, the COVID-19 pandemic has taught important lessons on the importance of infectious diseases and the critical need to build resilient health systems.

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

Acknowledgements: EXPLAIN study group: Erni J. Nelwan, Ralalicia Limato, Manzilina Mudia, Helio Guterres, Enty Enty, Ifael Y. Mauleti, Maria Mayasari, Iman Firmansyah, May Hizrani, Anis Karuniawati, Prof Taralan Tambunan, Prof Amin Soebandrio, Decy Subekti, Igbal Elyazar, Mutia Rahardjani, Fitria Wulandari, Prof Reinout van Crevel, Rogier van Doorn, Vu Thi Lan Huong, Nga Do Ti Thuy, Sonia Lewycka, Prof Alex Broom, Raph L. Hamers. Funding statement This work was funded by and RLH and HRVD are supported by the Wellcome Africa Asia Programme Vietnam (106680/Z/14/Z). RL is supported by an OUCRU Prize Studentship and a Nuffield Dept of Medicine Tropical Network Fund DPhil Bursary. Competing interest statement AK serves as the current Chair of the National AMR Committee (KPRA). HRVD serves as an Executive Board Member of The Surveillance and Epidemiology of Drug-resistant Infections Consortium (SEDRIC). The other authors declare no competing interests. **Author contributions** RLH conceived the idea for the study. RLH and RL obtained the funding. RL, PD and RLH designed the study protocol and data extraction instrument. PD, GL, MM, and MA collected and verified the data, overseen by RL and RLH, RL, GL and RLH performed the analysis and had full access to all study data. RL, GL, MA and RLH drafted the paper, with critical inputs from AK and HRvD. All authors critically revised the manuscript, and all authors gave approval for the final version to be published. **Data sharing statement**: No additional data are available. **ORCID IDs:** Ralalicia Limato 0000-0002-5306-3254 Gilbert Lazarus 0000-0002-3605-6167 Puck Dernison -Manzilina Mudia -Monik Alamanda -Erni J. Nelwan 0000-0003-4064-5412 Robert Sinto 0000-0003-3857-300X Anis Karuniawati 0000-0002-9882-2488 H. Rogier van Doorn 0000-0002-9807-1821 Hamers 0000-0002-5007-7896 Raph L.

555 **REFERENCES** 556 1 Christopher J L Murray, Kevin Shunji Ikuta, Fablina Sharara, Lucien Swetschinski, Gisela 557 Robles Aguilar, Authia Gray, Chieh Han, Catherine Bisignano, Puja Rao, Eve Wool, Sarah 558 C Johnson, Annie J Browne, Michael Give Chipeta, Frederick Fell, Sean Hackett,, MN. 559 Global burden of bacterial antimicrobial resistance in 2019 ☐: a systematic analysis. Lancet 560 2022; **399**: 629–55. 2 561 Aditi Sriram, Erta Kalanxhi, Geetanjali Kapoor, Jessica Craig, Ruchita Balasubramanian, 562 Sehr Brar, Nicola Criscuolo, Alisa Hamilton, Eili Klein, Katie Tseng, Thomas Van Boeckel 563 RL. The State of the World's Antibiotics 2021. 2021. 564 3 Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic 565 convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A 566 2018; **115**: E3463-70. 567 4 Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021; 27: 520-31. 568 569 5 Agustina R, Dartanto T, Sitompul R, et al. Universal health coverage in Indonesia: concept, 570 progress, and challenges. Lancet. 2019; 393: 75-102. 571 6 Mboi N, Murty Surbakti I, Trihandini I, et al. On the road to universal health care in 572 Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. 573 Lancet 2018; **392**: 581–91. 7 574 Parathon H, Kuntaman K, Widiastoety TH, et al. Progress towards antimicrobial resistance 575 containment and control in Indonesia. BMJ 2017; : j3808. 576 8 Ministry of Health Republic of Indonesia. National Action Plan on Antimicrobial Resistance 577 Indonesia 2017-2019. 2017 https://www.flemingfund.org/wp-578 content/uploads/59f148b0482cda160087e29b9a5a21a0.pdf. 579 9 Menteri Koordinator Bidang Pembangunan Manusia dan Kebudayaan Republik Indonesia. 580 Peraturan Menteri Koordinator Bidang Pembangunan Manusia dan Kebudayaan Republik 581 Indonesia Nomor 7 Tahun 2021 Tentang Rencana Aksi Nasional Pengendalian Resistensi 582 Antimikroba Tahun 2020-2024. 2021. https://jdih.kemenkopmk.go.id/sites/default/files/2021-

11/Permenko 7 2021 RAN PRA.pdf (accessed Feb 14, 2022).

583

584	10	Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated
585		guideline for reporting systematic reviews. BMJ 2021; 372. DOI:10.1136/bmj.n71.
586	11	World Health Organization (WHO). WHO releases the 2019 AWaRe Classification
587		Antibiotics. World Heal. Organ. 2019. https://www.who.int/news/item/01-10-2019-who-
588		releases-the-2019-aware-classification-antibiotics (accessed March 15, 2021).
589	12	Gyssens IC, Van Den Broek PJ, Kullberg BJ, Hekster YA, Van Der Meer JWM. Optimizing
590		antimicrobial therapy. A method for antimicrobial drug use evaluation. J Antimicrob
591		Chemother 1992; 30 : 724–7.
592	13	Van Der Meer JWM, Gyssens IC. Quality of antimicrobial drug prescription in hospital. Clin
593		Microbiol Infect 2001; 7: 12–5.
594	14	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
595		Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
596		statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–7.
597	15	Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different
598		types of systematic reviews: a guide for synthesisers of evidence. BMC Med. Res.
599		Methodol. 2021; 21 : 1–9.
600	16	Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rücker G. Seriously misleading results using
601		inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single
602		proportions. Res Synth Methods 2019; 10 : 476–83.
603	17	Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of
604		proportion studies, funnel plots were found to be an inaccurate method of assessing
605		publication bias. J Clin Epidemiol 2014; 67: 897–903.
606	18	Davey P, Scott CL, Brown E, et al. Interventions to improve antibiotic prescribing practices
607		for hospital inpatients (updated protocol). Cochrane Database Syst Rev 2017.
608		DOI:10.1002/14651858.CD011236.pub2.
609	19	Andriani Y, Meirista I, Aprio Y. Evaluasi Penggunaan Antibiotik dengan Metode ATC/DDD
610		dan DU 90% di Puskesmas Kebun Handil Kota Jambi Periode 2018 dan 2019. J Healthc
611		Technol Med 2020; 6 : 700.
612	20	Dirga D, Khairunnisa SM, Akhmad AD, Setyawan IA, Pratama A. Evaluasi Penggunaan

613		Antibiotik pada Pasien Rawat Inap di Bangsal Penyakit Dalam RSUD. Dr. H. Abdul Moeloek
614		Provinsi Lampung. <i>J Kefarmasian Indones</i> 2021; : 65–75.
615	21	Mahmudah F, Sumiwi SA, Hartini S. Study of the Use of Antibiotics with ATC/DDD System
616		and DU 90% in Digestive Surgery in Hospital in Bandung. <i>Indones J Clin Pharm</i> 2016; 5 :
617		293–8.
618	22	Massey FK, Yulia R, Herawati F. Profil Kualitas dan Kuantitas Penggunaan Antibiotik
619		Profilaksis pada Pre, On, dan Pos Bedah di Rumah Sakit Provinsi (RSP) NTB. J Sains
620		Farm Klin 2021; 8 : 43.
621	23	Narulita L, Bilal R, Akram M, Suharjono S. Analysis of Antibiotics on Patients Surgery,
622		before and after Used Guidelines for Antibiotics (PPAB). J Pharmascience 2020; 7: 51.
623	24	Perdaka W, Sagita D, Pratama S. Studi Penggunaan Antibiotik Berdasarkan ATC / DDD
624		Dan Du 90 % Di Puskesmas X Kota Jambi Periode 2017-2018 Study of Antibiotic Use
625		Based on ATC / DDD and Du 90 % in Community Health Centers X City OfJambi Period
626		2017-2018. J Healthc Technol Med 2020; 6 : 26–32.
627	25	Pratama NYI, Suprapti B, Ardhiansyah AO, Shinta DW. Analisis Penggunaan Antibiotik
628		pada Pasien Rawat Inap Bedah dengan Menggunakan Defined Daily Dose dan Drug
629		Utilization 90% di Rumah Sakit Universitas Airlangga. <i>Indones J Clin Pharm</i> 2019; 8 : 256.
630	26	Rachmawati S, Fazeri RL, Norcahyanti I. Gambaran Penggunaan Antibiotik di Bangsal
631		Penyakit Dalam RSUD Bangil Kabupaten Pasuruan. JPSCR J Pharm Sci Clin Res 2020;
632		01 : 12–21.
633	27	Sholih MG, Sudarjat H, Saula LS. Gambaran penggunaan antibiotik berdasarkan metode
634		ATC/DDD dan DU 90% di salah satu Puskesmas Karawang. <i>Heal Sci Growth</i> 2019; : 31–7.
635	28	Susanto M, Qanti PO, Anggraini D, Enda WG. Decline in Antibiotic Use after
636		Implementation of Restriction Program at Eka Hospital, Pekanbaru, Riau. In: The 5th
637		International Conference on Public Health. 2019: 1–7.
638	29	Trisia FJ, Sagita D, Pratama S, et al. Evaluasi Penggunaan Antibiotik Dengan Metode ATC
639		/ DDD Dan DU 90 % Di Dua Puskesmas Kota Jambi Periode 2017-2018 Evaluation Of
640		Antibiotic Use By Method ATC / DDD And DU 90 % In Two Health Centers Jambi Period
641		2017-2018. J Healthc Technol Med 2020; 6 : 125–38.

642	30	Wikantiananda T, Tjahjadi AI, Sudjud RW. Antibiotic Utilization Pattern in the Intensive Care
643		Unit of Tertiary Hospital in West Java, Indonesia. Int J Integr Heal Sci 2019; 7: 81–7.
644	31	Hadi U, Keuter M, HVA. Optimizing antibiotic usage in adults admitted with fever by a
645		multifaceted intervention in an Indonesian governmental hospital. Trop Med Int Heal 2008.
646		https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-3156.2008.02080.x (accessed May
647		10, 2019).
648	32	Herawati F, Yulia R, Hak E, et al. A Retrospective Surveillance of the Antibiotics
649		Prophylactic Use of Surgical Procedures in Private Hospitals in Indonesia. Hosp Pharm
650		2019; 54 : 323–9.
651	33	Kartika N, Lestari E, Farida H, Ciptaningtyas VR. Kualitas dan Kuantitas Penggunaan
652		Antibiotik pada Kasus Penyakit Dalam Sebelum dan Setelah Penyuluhan PPRA Di Rumah
653		Sakit Nasional Diponegoro. Diponegoro Med J (Jurnal Kedokt Diponegoro) 2019; 8: 1306-
654		18.
655	34	Kusuma A, Galistiani G, Wijayanti D. Evaluasi Kuantitatif Penggunaan Antibiotik pada
656		Pasien Caesarean Section di RSUD se-Kabupaten Banyumas. J Farm Indones 2016; 8.
657		http://www.jfionline.org/index.php/jurnal/article/view/245 (accessed May 8, 2019).
658	35	Putri Hadiningrat Ayunda, Akrom A, Risdiana I. Analisis penggunaan antibiotik pada pasien
659		Community-Acquired Pneumonia (CAP) di RS PKU Muhammadiyah Gamping. 2021
660		DOI:10.31603/PHARMACY.V7I1.3251.
661	36	Yulia R, Yuaraningtyas G, Wijono H. Profil penggunaan antibiotik dan peta kuman di ruang
662		rawat RS Husada Utama Surabaya. 2017. http://repository.ubaya.ac.id/31867/ (accessed
663		May 7, 2019).
664	37	Pradipta IS, Ronasih E, Kartikawati AD, et al. Three years of antibacterial consumption in
665		Indonesian Community Health Centers: The application of anatomical therapeutic
666		chemical/defined daily doses and drug utilization 90% method to monitor antibacterial use. J
667		Fam Community Med 2015; 22 : 101.
668	38	Muliani N, Herawati F, Yulia R, Wijono H. Quantity and quality profiles of antibiotics pre, on,
669		and post surgery in a hospital setting. Int J Clin Pharm 2021. DOI:10.1007/s11096-021-
670		01251-0.

671	39	Adani NL, Arkhaesi N, Anam M. Hubungan usia anak dan diagnosis dengan rasionalitas
672		penggunaan antibiotik pada pasien anak di Puskesmas Rowosari Semarang. J Kedokt
673		Diponegoro 2015; 4 : 1277–85.
674	40	Magdalena R, Bachtiar A. Antimicrobial Resistance Control Program on The Rational Use
675		of Antibiotics In Eka Hospital Pekanbaru, Indonesia. publications.inschool.id 2018.
676		http://publications.inschool.id/index.php/icash/article/view/258 (accessed May 9, 2019).
677	41	Yoanitha N, Wirakusumah F, Sukarsa R. Gambaran Rasionalitas Penggunaan Antibiotik
678		berdasarkan Kriteria Gyssens di Bangsal Obstetri dan Ginekologi RSUP Dr. Hasan Sadikin
679		Bandung. obgynia.com 2018.
680		http://www.obgynia.com/obgyn/index.php/obgynia/article/view/37 (accessed May 9, 2019).
681	42	Setiawan S, Widyati W, Harijono P. Profil Penggunaan Antibiotik Pascapencanangan
682		Penerapan Program Pengendalian Resistensi Antibiotik di Intensive Care Unit Rumah Sakit
683		TNI-AL dr. Ramelan. J Farm Klin Indones 2018; 7 : 30–7.
684	43	Purwaningsih AEDA, Rahmawati F, Wahyono D. Evaluasi Penggunaan Antibiotik Pada
685		Pasien Pediatri Di Bangsal Rawat Inap Rumah Sakit Islam Sultan Agung Semarang. 2015.
686		http://etd.repository.ugm.ac.id/index.php?act=view&buku_id=83867&mod=penelitian_detail
687		⊂=PenelitianDetail&typ=html (accessed May 9, 2019).
688	44	Muthoharoh A, lana ND, Rahmatullah S, Wirasti W. Evaluasi kualitatif penggunaan
689		antibiotika profilaksis di instalasi bedah sentral secara retrospektif. 2019
690		http://repository.urecol.org/index.php/proceeding/article/view/386 (accessed May 8, 2019).
691	45	Hanifah H, Sari I, Nuryastuti T. Evaluasi Penggunaan Antibiotik Empiris dan Analisis Biaya
692		Demam Tifoid di Sebuah RS Swasta Kota Semarang. jsfk.ffarmasi.unand.ac.id 2018; 5: 1-
693		6.
694	46	Inez A, Susanti Program Studi Farmasi R, Kedokteran Universtas Tanjungpura JI Profesor
695		Dokter Hadari Nawawi FH, et al. Evaluasi Rasionalitas Penggunaan Antibiotik pada Pasien
696		Anak Rawat Inap di Rumah Sakit Universitas Tanjungpura Periode Januari-Juni 2018
697		Evaluation of Antibiotic Rationality for Pediatric Inpatient at Hospital of Tanjungpura
698		University Period. 2019 https://jurnal.untan.ac.id/index.php/jmfarmasi/article/view/37615
699		(accessed Feb 7, 2021).

700	47	Rosdiana D, Anggraini D, Balmas M, Effendi D, Bet A. Peningkatan Rasionalitas
701		Penggunaan Antibiotik Pasca Implementasi Kebijakan Penggunaan Antimikroba di RSUD
702		Arifin Achmad Pekanbaru. <i>J Kedokt Brawijaya</i> 2018; 30 : 36–40.
703	48	Aljufri AQ, Yasin NM, Wahyono D. Rasionalitas Terapi Antibiotik Empiris Pada Pasien
704		Pneumonia di Instalasi Rawat Inap RSUP Dr. Kariadi Semarang. Maj Farm 2021; 17: 89.
705	49	Anggraini ENF, Wicaksono A, Armyanti I. Rasionalitas Penggunaan Antibiotik pada Kasus
706		Typhus Abdominalis di Puskesmas Siantan Hilir Kota Pontianak Tahun 2014. <i>J Mhs PSPD</i>
707		FK Univ Tanjungpura 2018; 2. http://jurnal.untan.ac.id/index.php/jfk/article/view/23543
708		(accessed May 8, 2019).
709	50	Hardiana I, Ratih Laksmitawati D, Utami Ramadaniati H, et al. Evaluasi penggunaan
710		antibiotika pada pasien pneumonia komunitas di instalasi rawat inap RSPAD Gatot Subroto.
711		<i>Orig Artic MFF</i> 2021; 25 : 1–6.
712	51	Waridiarto DS, Agus Priambodo, Endang Sri Lestari. Kualitas penggunaan antibiotik pada
713		kasus bedah orthopedi di bangsal bedah RSUP Dr. Kariadi. Media Med Muda 2015; 4:
714		618–25.
715	52	Maakh DT, Da A, Fraga SS, Firdaus A. Rationality Evaluation of The Use of Prophylactic
716		Antibiotics In Sectio Caesarea Patients In Hospitals. Mgr. Gabriel Manek, Svd Atambua in
717		2018. Universitas Citra Bangsa, 2019 http://www.cyber-
718		chmk.net/ojs/index.php/farmasi/article/view/641 (accessed Feb 4, 2021).
719	53	Ibrahim AM, Widyati W, Prasetyadi FOH. Analisis Kualitatif Penggunaan Antibiotik pada
720		Pasien Rujukan dengan Metode Analisis Alur Gyssen di RSPAL Dr. Ramelan Surabaya.
721		MPI (Media Pharm Indones 2020; 3 : 88.
722	54	Sumiwi SA. Quality of Antibiotics Use in Patients with Digestive Surgery in Hospital in
723		Bandung City. Indones J Clin Pharm 2014; 3: 135–40.
724	55	Sutrisno E, Humardewayanti R, Bayupurnama P. Impact of irrational antibiotic therapy to
725		hospital cost of care of pneumonia in patients in Dr. Sardjito Hospital. Acta Interna J Intern
726		Med 2013; 3 : 67–71.
727	56	Harartasyahrani RA, Simamora S. Evaluasi penggunaan antibiotik profilaksis pada pasien
728		bedah kategori highly recommended di rumah sakit "X" kota Prabumulih. <i>J Muara Sains</i> ,

729		Teknol Kedokt dan Ilmu Kesehat 2021; 5 : 121.
730	57	Ovikariani S, Saptawat T, Rahma FA. Evaluasi Rasionalitas Penggunaan Antibiotik Pada
731		Pasien Ispa Di. J Ilmu Keperawatan dan Kebidanan STIKES Telogorejo 2019; XI: 76–82.
732	58	Ofisya M, Laviesta, Susanti R, Purwanti NU. Evaluasi penggunaan antibiotik pada pasien
733		pneumonia rawat inap di RSUD dr. Soedarso Pontianak. 2020
734		https://jurnal.untan.ac.id/index.php/jmfarmasi/article/view/42256 (accessed Feb 7, 2021).
735	59	Grassella, Yuswar MA, Purwanti NU. Studi rasionalitas penggunaan antibiotik dan interaksi
736		obat pada pasien anak terdiagnosis Infeksi Saluran Pernapasan Akut (ISPA) di instalasi
737		rawat jalan RSUD Sultan Syarif Mohamad Alkadrie Pontianak tahun 2018. <i>J Mhs Farm Fak</i>
738		Kedokt UNTAN 2019; 4. https://jurnal.untan.ac.id/index.php/jmfarmasi/article/view/35316
739		(accessed Feb 7, 2021).
740	60	Hasyul SFP, Puspitan T, Nuari DA, Muntaqin EP, Wartini E, Eka MY. Evaluasi penggunaan
741		obat antibiotik pada pasien demam tifoid di Kabupaten Garut pada Januari-Desember 2017.
742		J Ilm Farm Bahari 2019; 10 : 160–70.
743	61	Jamiati J, Abadi H, Sari M. Evaluasi Peresepan Antibiotik Pada Pasien Rawat Jalan di
744		Puskesmas Dabun Gelang Kabupaten Gayo Lues. J Dunia Farm 2019; 3: 115–22.
745	62	Fakhrunnisa F, Andrajadi R, Radji M. Quality of Antibiotic Prescribing for Respiratory Tract
746		Disease in Primary Healthcare Centers in the District of Tegal, Central Java, Indonesia.
747		Indones J Clin Pharm 2020; 9: 95.
748	63	Anggraini AB, Syachroni. Penggunaan Antibiotik Profilaksis pada Bedah Bersih di Rumah
749		Sakit di Jakarta. J Penelit dan Pengemb Pelayanan Kesehat 2020; 4: 7–12.
750	64	Dewi R, Sutrisno D, Medina F, et al. Evaluasi Penggunaan Antibiotik Infeksi Saluran
751		Pernapasan Atas pada Anak di Puskesmas Olak Kemang Kota Jambi Tahun 2018
752		Evaluation of Antibiotic Use for Upper Respiratory Tract Infections in Children in Olak
753		Kemang Public Health Center, Jambi in 2018. 2020
754		DOI:10.30595/PHARMACY.V17I1.6936.
755	65	Dewi R, Sutrisno D, Purnamasari R. Evaluasi Penggunaan Antibiotik pada Pasien Balita
756		dengan Diagnosa Infeksi Saluran Pernapasan Atas di Puskesmas Koni Kota Jambi. <i>J Sains</i>
757		Kes 2020 2020; 2 : 385–90.

758	66	Kaparang PC, Tjitrosantoso H, Yamlean PV. Evaluasi kerasionalan penggunaan antibiotika
759		pada pengobatan pneumonia anak di instalasi rawat inap RSUP Prof. Dr. R. D. Kandou
760		manado periode Januari-Desember 2013. PHARMACON 2014; 3.
761		https://ejournal.unsrat.ac.id/index.php/pharmacon/article/view/5440 (accessed May 13,
762		2019).
763	67	Herlina D, Hasina R, Dewi NMAR. Pola peresepan antibiotik pada pasien infeksi saluran
764		kemih di instalasi rawat jalan RSUD Provinsi NTB tahun 2017. Sasambo J Pharm 2021; 2:
765		11–5.
766	68	Zazuli Z, Sukandar EY, Lisni I. Evaluasi Penggunaan Obat pada Pasien Bedah di Suatu
767		Rumah Sakit Swasta di Bandung. J Farm Klin Indones 2015; 4: 87–97.
768	69	Islam Z, Qodariyah SM, Nursehah ENE. Penggunaan Antibiotik Pada Terapi Community
769		Acquired Pneumonia di RSUD Pasar Rebo dan RSUD Tarakan di Jakarta Tahun 2014. J
770		Sains dan Teknol Farm 2017; 19: 1–8.
771	70	Dania H, Baroroh F, Bachri MS. Evaluasi Penggunaan Antibiotik Pada Pasien Bedah Sesar
772		Di Rumah Sakit PKU Muhammadiyah Bantul Yogyakarta. Pharm J Farm Indones 2016; 13.
773		https://www.neliti.com/id/publications/161113/evaluasi-penggunaan-antibiotik-pada-pasien-
774		bedah-sesar-di-rumah-sakit-pku-muhamm (accessed May 10, 2019).
775	71	Nyoman SMH N, Sumarsono T, Wahidatun N. Study on Use of Antibiotics for the Treatment
776		of Acute Respiratory Infections (ARIs) in Children at a Clinic in Bandung, Indonesia. Res J
777		Pharm Biol Chem Sci 2017; 8: 158.
778	72	Andrajati R, Tilaqza A, Supardi S. Factors related to rational antibiotic prescriptions in
779		community health centers in Depok City, Indonesia. <i>J Infect Public Health</i> 2016; 10 : 41–8.
780	73	Dewi RS, Radji M, Andalusia R. Evaluation of Antibiotic Use Among Sepsis Patients in an
781		Intensive Care Unit: A cross-sectional study at a referral hospital in Indonesia. Sultan
782		Qaboos Univ Med J [SQUMJ] 2018; 18 : 367.
783	74	Bakhtiar, Makaba S, Hasmi, Mallongi A. Rationality of Antibiotic Drug Used to Medical
784		Patient Post-Operatively in Selebe Solu Hospital Sorong City Papua Barat Province 2018.
785		Int J Sci Healthc Res 2019; 4.
786		http://ijshr.com/IJSHR_Vol.4_Issue.1_Jan2019/IJSHR0022.pdf (accessed May 9, 2019).

787	75	Sugiarti T, Sidemen A, Wiratmo. Studi Penggunaan Antibiotik pada Pasien Penyakit ISPA
788		Usia Bawah Lima Tahun di Instalasi Rawat Jalan Puskesmas Sumbersari Periode 1
789		Januari-31 Maret 2014. jurnal.unej.ac.id 2015.
790		https://jurnal.unej.ac.id/index.php/JPK/article/view/2583 (accessed May 9, 2019).
791	76	Rusdiana N, Safitri M, Resti A. Evaluasi penggunaan antibiotika profilaksis pada pasien
792		bedah sesar terencana di rumah sakit ibu dan anak "x" di Tangerang. Soc Clin Pharm
793		Indones J 2016. http://journal.uta45jakarta.ac.id/index.php/SCPIJ/article/view/275
794		(accessed May 9, 2019).
795	77	Oktaviani F, Wahyono D, Yuniarti E. Evaluasi penggunaan antibiotik profilaksis terhadap
796		kejadian infeksi luka operasi pada operasi sectio caesarea. J Manaj DAN PELAYANAN
797		Farm (Journal Manag Pharm Pract 2015. https://journal.ugm.ac.id/jmpf/article/view/29449
798		(accessed May 7, 2019).
799	78	Kurniawati H, Auliyanah A. Pattern of antibiotics use in adult patients with Urinary Tract
800		Infection (UTI). 2021 DOI:10.20527/JBK.V17I1.10244.
801	79	Bestari MP, Karuniawati H. Evaluasi Rasionalitas dan Efektifitas Penggunaan Antibiotik
802		pada Pasien Pneumonia Pediatrik di Instalasi Rawat Inap Rumah Sakit Pusat Jawa
803		Tengah. Pharmacon J Farm Indones 2019; 14. DOI:10.23917/pharmacon.v14i2.6524.
804	80	Limato R, Nelwan EJ, Mudia M, et al. A multicentre point prevalence survey of patterns and
805		quality of antibiotic prescribing in Indonesian hospitals. <i>JAC-Antimicrobial Resist</i> 2021; : 1–
806		10.
807	81	Ridha Elvina, Nur Rahmi, Sandra Ayu Oktavira. Evaluasi penggunaan antibiotik pada
808		pasien Community-Acquired Pneumonia (CAP) di instalasi rawat inap rumah sakit 'X'
809		Jakarta. <i>Pharmacy</i> 2017; 14 : 64–74.
810	82	Risha Fillah Fithria, Akroman Rohmat Di'fain. Rasionalitas terapi antibiotik pada pasien
811		diare akut anak usia 1-4 tahun di rumah sakit Banyumanik Semarang tahun 2013.
812		Pharmacy 2015; 12 : 197–209.
813	83	Nawakasari N, Nugraheni AY. Evaluasi Penggunaan Antibiotik pada Pasien Infeksi Saluran
814		Kemih di Instalasi Rawat Inap RSUP X di Klaten Tahun 2017. Pharmacon J Farm Indones
815		2019; 16 : 38–48.

816	84	Octavia DR. Evaluasi Penggunaan Antibiotika Profilaksis pada Pasien Bedah Sesar.
817		Indones J Heal Res 2019; 2 : 23–30.
818	85	Benua GP, Tiwow GAR, Untu SD, Karauwan FA. Evaluasi Rasionalitas Penggunaan
819		Antibiotik Pada Pasien ISPA Di Puskesmas Tonusu Kecamatan Pamona Puselemba
820		Kabupaten Poso. J Biofarmasetikal Trop 2019; 2019: 136–40.
821	86	Karuniawati H, Yulianti T, Aini DK, Nurwienda FI. Impact of antimicrobial stewardship
822		program on the use of antibiotics in pneumonia patients at teaching hospital in surakarta
823		Indonesia. Int J Appl Pharm 2021; 13 : 20–3.
824	87	Farida H, Herawati H, Hapsari M, Notoatmodjo H, Hardian H. Penggunaan Antibiotik
825		Secara Bijak Untuk Mengurangi Resistensi Antibiotik, Studi Intervensi di Bagian Kesehatan
826		Anak RS Dr. Kariadi. Sari Pediatr 2016; 10: 34.
827	88	Hapsari M, Farida H, Keuter M, PJ B, Pediatri UH-S, 2016 U. Penurunan Penggunaan
828		Antibiotik pada Pasien Anak dengan Demam. Sari Pediatr 2006.
829		https://saripediatri.org/index.php/sari-pediatri/article/download/816/751 (accessed May 7,
830		2019).
831	89	Murni IK, Duke T, Kinney S, Daley AJ, Soenarto Y. Reducing hospital-acquired infections
832		and improving the rational use of antibiotics in a developing country: an effectiveness study.
833		<i>Arch Dis Child</i> 2015; 100 : 454–9.
834	90	King J, Ciptaningtyas VR. Kuantitas penggunaan antibiotik sebelum dan setelah pembuatan
835		Pedoman Penggunaan Antibiotik (PPAB). Penelitian pada kasus bedah digestif RSUP Dr.
836		Kariadi Semarang. J Kedokt Diponegoro 2015; 4: 1072-82.
837	91	Lizikri A, Arozal W, Ramadaniati HU. Effects of Clinical Pathway Implementation in
838		Management of Pediatric Inpatients with Pneumonia: A Cross-Sectional Study in Indonesia.
839		Int J Res Pharm Sci 2020; 11 : 7281–8.
840	92	Dwiprahasto I. Ketersediaan obat di kabupaten dan mutu peresepan di pusat pelayanan
841		kesehatan primer. Berkala Ilmu Kedokteran 2004. http://i-
842		lib.ugm.ac.id/jurnal/detail.php?datald=3283 (accessed May 9, 2019).
843	93	Widowati I, Wirawan I, Nopiyani N, Sari K. Pharmacist counseling intervention to improve
844		patient antibiotic compliance. phpmajournal.org 2018.

845		https://phpmajournal.org/index.php/phpma/article/view/158 (accessed May 9, 2019).
846	94	Artini I, Indrayani A. Penggunaan antibiotika secara mandiri pada mahasiswa kedokteran
847		dan non kedokteran Universitas Udayana. ojs.unud.ac.id 2016.
848		https://ojs.unud.ac.id/index.php/ach/article/view/27464 (accessed May 9, 2019).
849	95	Djawaria DAP, Setiadi AP, Setiawan E. Analisis Perilaku dan Faktor Penyebab Perilaku
850		Penggunaan Antibiotik Tanpa Resep di Surabaya Behavior Behavior Analysis and
851		Attributed Factors to Non Prescription Antibiotic Used in Surabaya. <i>J MKMI</i> 2018; 14 .
852		DOI:10.30597/mkmi.v14i4.5080.
853	96	Kurniawan K, Posangi J, Rampengan N. Association between public knowledge regarding
854		antibiotics and self-medication with antibiotics in Teling Atas Community Health Center,
855		East Indonesia. Med J Indones 2017; 26: 62.
856	97	Novelni R, Azyenela L, Septiana Y. Hubungan tingkat pendidikan masyarakat terhadap
857		pengetahuan dalam penggunaan antibiotik oral di apotek Kecamatan Koto Tangah Padang.
858		J Penelit Farm Indones 2020; 9: 2020.
859	98	Nuraini A, Yulia R, Herawati F, Setiasih S. The Relation between Knowledge and Belief with
860		Adult Patient's Antibiotics Use Adherence. J Manaj DAN PELAYANAN Farm (Journal
861		Manag Pharm Pract 2019; 8: 165.
862	99	Pratama AN, Rohmawati A, Rachmawati E. A survey of antibiotics purchased without
863		prescription among non-health science students in Jember, Indonesia. J Farm Sains dan
864		Komunitas 2018. https://e-journal.usd.ac.id/index.php/JFSK/article/view/1032 (accessed
865		May 9, 2019).
866	100	Salsabila NN, Kristina SA. Awareness on antibiotic resistance among lay people in
867		Yogyakarta, Indonesia. Int Jounral Pharm Res 2021; 12: 180-8.
868	101	Siahaan S, Usia T, Pujiati S, et al. Pengetahuan, sikap, dan perilaku masyarakat dalam
869		memilih obat yang aman di tiga Provinsi di Indonesia. neliti.com 2017.
870		https://www.neliti.com/publications/178574/pengetahuan-sikap-dan-perilaku-masyarakat-
871		dalam-memilih-obat-yang-aman-di-tiga-p (accessed May 7, 2019).
872	102	Tandjung H, Wiyono WI, Mpila DA. Pengetahuan dan penggunaan antibiotik secara
873		swamedikasi pada masyarakat di kota Manado. 2021 DOI:10.35799/PHA.10.2021.34044.

874	103	WHO. Antibiotic Resistance: Multi-Country Public Awareness Survey. WHO Press 2015; :
875		1–51.
876	104	Widayati A, Suryawati S, de Crespigny C, Hiller JE. Self medication with antibiotics in
877		Yogyakarta City Indonesia: a cross sectional population-based survey. BMC Res Notes
878		2011; 4 : 491.
879	105	Widayati A, Suryawati S, de Crespigny C, Hiller JE. Knowledge and beliefs about antibiotics
880		among people in Yogyakarta City Indonesia: a cross sectional population-based survey.
881		Antimicrob Resist Infect Control 2012; 1: 38.
882	106	Fatmah S, Aini SR, Pratama IS. Tingkat Pengetahuan Mahasiswa Tahun Pertama Bersama
883		(TPB) tentang Penggunaan Antibiotik dalam Swamedikasi. <i>J Sains Farm Klin</i> 2019; 6 : 200.
884	107	Yulia R, Putri R, Wahyudi R. Studi Tingkat Pengetahuan Masyarakat terhadap Penggunaan
885		Antibiotik di Puskesmas Rasimah Ahmad Bukittinggi. J Pharm Sci 2019; 2: 43–8.
886	108	Yuliani NN, Wijaya C, Moeda G. Tingkat pengetahuan masyarakat RW IV Kelurahan
887		Fontein Kota Kupang terhadap penggunaan antibiotik. 2014
888		https://media.neliti.com/media/publications/259672-tingkat-pengetahuan-masyarakat-rwiv-
889		kelu-a98691f1.pdf (accessed May 10, 2019).
890	109	Fernandez ABM. Studi Penggunaan Antibiotik Tanpa Resep Di Kabupaten Manggarai dan
891		Manggarai Barat – NTT. 2013; 2 : 1–17.
892	110	Fimanggara B, Istriati, Diposarosa R. Knowledge and Attitude towards Antibiotic Use
893		among College Students in Jatinangor. journal.fk.unpad.ac.id 2016.
894		http://journal.fk.unpad.ac.id/index.php/amj/article/view/792 (accessed May 9, 2019).
895	111	Fitriah R, Mardiati N, Tinggi S, et al. Pengaruh faktor sosiodemografi terhadap pengetahuan
896		dan sikap pada penggunaan antibiotik di kalangan masyarakat pedesaan: Studi
897		observasional di kecamatan Cempaka Banjarbaru. 2021
898		DOI:10.31603/PHARMACY.V7I1.3181.
899	112	Hamid F, Rasmin Kotto F, Prasetia W. Karakteristik Pengguna Antibiotik tanpa Resep
900		Dokter di Kalangan Guru Kecamatan Labakkang, Kabupaten Pangkajene dan Kepulauan.
901		2020 DOI:10.24252/ALAMI.V4I2.15157.
902	113	Insany AN, Dika P. Destiani, Anwar Sani, Lilik Sabdaningtyas, Ivan S. Pradipta. Association

903 between Perceived Value and Self-Medication with Antibiotics: An Observational Study 904 Based on Health Belief Model Theory. J Farm Klin Indones 2015; 4: 77–86. 905 114 Kondoj IV, Lolo WA, Jayanto I. Pengaruh Tingkat Pengetahuan Dan Sikap Terhadap 906 Penggunaan Antibiotik Di Apotek Kimia Farma 396 Tuminting Kota Manado. Pharmacon 907 2020; **9**. 908 115 Kristina SA, Wati R, Prasetyo SD, Fortwengel G. Public knowledge and awareness towards 909 antibiotics use in Yogyakarta: A cross sectional survey. Pharm Sci Asia 2020. 910 DOI:10.29090/psa.2020.02.019.0008. 911 116 Asvinigita LRM, Ikapuspitasari;, Kristina SA. Antibiotics stewardship practice among 912 community pharmacists in indonesia: A cross-sectional survey. Int J Pharm Res 2019; 11: 913 176-81. 914 117 Siswati S. Analisis penggunaan antibiotika yang tidak rasional pada balita penderita bukan 915 penumonia di kota Padang, Lembaga Penelitian, Universitas Negeri Padang, 2009 916 http://ejournal.unp.ac.id/index.php/sainstek/article/view/153 (accessed May 8, 2019). 917 118 Zhang J, Cameron D, Quak SH, et al. Rates and determinants of antibiotics and probiotics prescription to children in Asia-Pacific countries. Benef Microbes 2020; 11: 329-38. 918 919 Wulandari LPL, Khan M, Liverani M, et al. Prevalence and determinants of inappropriate 119 920 antibiotic dispensing at private drug retail outlets in urban and rural areas of Indonesia: A 921 mixed methods study. BMJ Glob Heal 2021; 6: 1-11. 922 Arshad M, Mahmood SF, Khan M, Hasan R. Covid -19, misinformation, and antimicrobial 120 923 resistance. *BMJ* 2020; **371**: 1–2. 924 121 CDDEP. Resistance Map: Indonesia Use Data. 2021. 925 https://resistancemap.cddep.org/CountryPage.php?countryId=77&country=Indonesia+ 926 (accessed May 31, 2021). 927 122 Thamlikitkul V, Rattanaumpawan P, Sirijatuphat R, Wangchinda W. Integrated one-day 928 surveillance of antimicrobial use, antimicrobial consumption, antimicrobial resistance, 929 healthcare-associated infection, and antimicrobial resistance burden among hospitalized 930 patients in Thailand. J Infect 2020; 81: 98-106. 931 123 Singh SK, Sengupta S, Antony R, et al. Variations in antibiotic use across India: multi-centre 932 study through Global Point Prevalence survey. J Hosp Infect 2019; 103: 280–3. 933 124 Saleem Z, Hassali MA, Versporten A, et al. A multicenter point prevalence survey of 934 antibiotic use in Punjab, Pakistan: findings and implications. Expert Rev Anti Infect Ther 935 2019; **17**: 285–93. 936 125 Xie D shuang, Xiang L li, Li R, Hu Q, Luo Q gin, Xiong W. A multicenter point-prevalence 937 survey of antibiotic use in 13 Chinese hospitals. J Infect Public Health 2015; 8: 55-61. 938 126 Thu TA, Rahman M, Coffin S, Harun-Or-Rashid M, Sakamoto J, Hung NV. Antibiotic use in 939 Vietnamese hospitals: A multicenter point-prevalence study. Am J Infect Control 2012; 40: 940 840-4. 941 Versporten A, Zarb P, Caniaux I, et al. Antimicrobial consumption and resistance in adult 127 942 hospital inpatients in 53 countries: results of an internet-based global point prevalence 943 survey. Lancet Glob Heal 2018; 6: e619-29. 944 128 Saleem Z, Hassali MA, Godman B, et al. Point prevalence surveys of antimicrobial use: a systematic review and the implications. Expert Rev Anti Infect Ther 2020; 18: 897-910. 945 946 129 Klein EY, Milkowska-Shibata M, Tseng KK, et al. Assessment of WHO antibiotic 947 consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical 948 sales data. Lancet Infect Dis 2021; 21: 107–15. 949 Schwartz KL, Langford BJ, Daneman N, et al. Unnecessary antibiotic prescribing in a 130 950 Canadian primary care setting: a descriptive analysis using routinely collected electronic 951 medical record data. C Open 2020; 8: E360-9. 952 131 Gasson J, Blockman M, Willems B. Antibiotic prescribing practice and adherence to 953 guidelines in primary care in the cape town Metro district, South Africa. South African Med J 954 2018; **108**: 304–10. 955 132 Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary 956 health care settings in China. JAMA Intern Med 2014; 174: 1914–20. 957 133 Sarwar MR, Sagib A, Iftikhar S, Sadiq T. Antimicrobial use by WHO methodology at primary 958 health care centers: a cross sectional study in Punjab, Pakistan. BMC Infect Dis 2018; 18: 959 1-9. 960 134 Minh NNQ, van Toi P, Qui LM, et al. Antibiotic use and prescription and its effects on

961 Enterobacteriaceae in the gut in children with mild respiratory infections in Ho Chi Minh City, 962 Vietnam. A prospective observational outpatient study. PLoS One 2020: 15: 1–18. 963 135 Sulis G, Adam P, Nafade V, et al. Antibiotic prescription practices in primary care in low-964 And middle-income countries: A systematic review and meta-analysis. PLoS Med 2020; 17: 965 1-20. 966 136 Chaw PS, Höpner J, Mikolajczyk R. The knowledge, attitude and practice of health 967 practitioners towards antibiotic prescribing and resistance in developing countries—A 968 systematic review. J Clin Pharm Ther 2018; 43: 606–13. 969 137 Md Rezal RS, Hassali MA, Alrasheedy AA, Saleem F, Md Yusof FA, Godman B. 970 Physicians' knowledge, perceptions and behaviour towards antibiotic prescribing: a 971 systematic review of the literature. Expert Rev Anti Infect Ther 2015; 13: 665–80. 972 Monnier AA, Eisenstein BI, Hulscher ME, Gyssens IC. Towards a global definition of 138 973 responsible antibiotic use: Results of an international multidisciplinary consensus 974 procedure. J Antimicrob Chemother 2018: 73: vi3–16. 975 Le Maréchal M, Tebano G, Monnier AA, et al. Quality indicators assessing antibiotic use in 139 976 the outpatient setting: A systematic review followed by an international multidisciplinary 977 consensus procedure. J Antimicrob Chemother 2018; 73: vi40–9. 978 Schuts EC, Hulscher MEJL, Mouton JW, et al. Current evidence on hospital antimicrobial 140 979 stewardship objectives: A systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 980 847-56. 981 141 Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. Systematic review and meta-982 analysis of clinical and economic outcomes from the implementation of hospital-based 983 antimicrobial stewardship programs. Antimicrob Agents Chemother 2016; **60**: 4840–52. 984 142 Hospital Accreditation Committee. Standard Hospital Accreditation 1st Edition. 2017. 985 143 Herawati F, Ananta SC, Parwitha IAA, et al. Interview-based cross-sectional needs 986 assessment to advance the implementation of an effective antibiotic stewardship program in 987 Indonesian hospitals. Heal Policy OPEN 2020; 1: 100002. 988 144 Lee TH, Lye DC, Chung DR, et al. Antimicrobial stewardship capacity and manpower needs 989 in the Asia Pacific. J Glob Antimicrob Resist 2021; 24: 387–94.

990	145	Ministry of Health Republic of Indonesia. Peraturan Menteri Kesehatan Republik Indonesia
991		Nomor 8 Tahun 2015 Tentang Program Pengendalian Resistensi Antimikroba di Rumah
992		Sakit. Indonesia, 2015.
993	146	Direktorat Pelayanan Kesehatan Rujukan DJPKKKRI. Panduan Penatagunaan Antimikroba
994		di Rumah Sakit Edisi 1. 2021.
995	147	Wilkinson A, Ebata A, Macgregor H. Interventions to Reduce Antibiotic Prescribing in
996		LMICs: A Scoping Review of Evidence from Human and Animal Health Systems. Antibiot
997		(Basel, Switzerland) 2018; 8. DOI:10.3390/ANTIBIOTICS8010002.
998	148	Van Katwyk SR, Grimshaw JM, Nkangu M, et al. Government policy interventions to reduce
999		human antimicrobial use: A systematic review and evidence map. <i>PLOS Med</i> 2019; 16 :
1000		e1002819.
1001	149	US Department of Health and Human Services, CDC. Core elements of hospital antibiotic
1002		stewardship programs. US Dep Heal Hum Serv CDC 2019; : 40.
1003	150	Dijck C Van, Vlieghe E, Janneke &, Cox A. Systematic reviews Antibiotic stewardship
1004		interventions in hospitals in low-and middle-income countries: a systematic review. Bull
1005		World Heal Organ 2018; 96 : 266–80.
1006	151	Burke JP. Antibiotic Resistance — Squeezing the Balloon□? <i>Jama</i> 1998; 280 : 1270–1.
1007	152	Auta A, Hadi MA, Oga E, et al. Global access to antibiotics without prescription in
1008		community pharmacies: A systematic review and meta-analysis. <i>J Infect</i> 2019; 78 : 8–18.
1009	153	Nepal G, Bhatta S. Self-medication with Antibiotics in WHO Southeast Asian Region: A
1010		Systematic Review. Cureus 2018; 10: e2428.
1011	154	Chua AQ, Verma M, Hsu LY, Legido-Quigley H. An analysis of national action plans on
1012		antimicrobial resistance in Southeast Asia using a governance framework approach. Lancet
1013		Reg Heal - West Pacific 2021; 7 : 100084.
1014	155	WHO. Global antimicrobial resistance and use surveillance system (GLASS) report.
1015		Geneva, 2021 http://www.who.int/glass/resources/publications/early-implementation-report-
1016		2020/en/.
1017	156	Ministry of Health Republic of Indonesia. Peraturan Menteri Kesehatan Republik Indonesia
1018		Nomor 28 Tahun 2021 Tentang Pedoman Penggunaan Antibiotik. 2021.

1019	157	Bloom G, Merrett GB, Wilkinson A, Lin V, Paulin S. Antimicrobial resistance and universal
1020		health coverage. BMJ Glob Heal 2017; 2: e000518.
1021	158	ReAct - Action on Antibiotic Resistance. Antimicrobial resistance and universal health
1022		coverage What's the deal? 2019 https://www.reactgroup.org/wp-
1023		content/uploads/2019/09/Antimicrobial-resistance-and-universal-health-coverage-Whats-
1024		the-deal-ReAct-Sept-2019.pdf (accessed Dec 26, 2021).
1025		

FIGURE LEGEND Figure 1. PRISMA flowchart of study selection Figure 2. Geographical map of the 100 included reports on antibiotic use in Indonesia 2000-2021 The map includes 2 KAP surveys that were conducted nationwide, and 1 AMS study and 1 KAP survey that were conducted in multiple provinces. Figure 3. Summary forest plot of reports on antibiotic consumption The figure summarizes 20 reports in the domain antibiotic consumption, expressed as DDD/100 patient-days, for the top-15 antibiotics. Egger's tests to assess publication bias could only be performed for the primary analysis and the individual AWaRe antibiotics. Abbreviations: CI, confidence interval; DDD, defined daily dose; NA, not applicable. Figure 4. Summary forest plot on prescribing appropriateness The figure summarizes 49 reports in the domain prescribing appropriateness based on Gyssens method (A) or references guidelines (B). Indicators (B) were reported by different numbers of studies. Egger's tests to assess publication bias in Gyssens method (A) could only be performed for the primary analysis. Abbreviations: Cl. confidence interval: NA. not applicable.

Figure 1. PRISMA flowchart of study selection.





Figure 2. Geographical map of the 100 included reports on antibiotic use in Indonesia 2000-2021



The map includes 2 KAP surveys that were conducted nationwide, and 1 AMS study and 1 KAP survey that were conducted in multiple provinces.

Figure 3. Summary forest plot of reports on antibiotic consumption


Variable	N	Total	DDD/100 patient-days	95% CI		12 (%)	Egger's test p-value
Health care setting	8				v	1,1	
Primary care	5	5183957	37.8	25.9; 49.8		100	NA
Hospital	15	9669	134.1	88.7 ; 179.6		→ 100	NA
Study location							
Java	14	5182050	114.4	70.7 ; 158.0	1 1 1 1 1 1	→ 100	NA
Non-Java	6	11576	100.0	68.7 ; 131.3		100	NA
Year of publication							
<2016	4	5178773	55.2	18.5;91.9		100	NA
≥2016	16	14853	123.8	100.2 ; 147.3		100	NA
Access antibiotics							
Chloramphenicol	4	5179904	4.4	3.7;5.1	•	100	NA
Amoxicillin	12	5191728	12.4	6.5; 18.4	-	100	0.093
Ampicillin	2	1220	28.0	0.0;82.8		100	NA
Cefazolin	7	7431	3.2	1.0;5.5	•	100	NA
Cefadroxil	7	7521	2.6	1.2;4.0		100	NA
Gentamicin	10	7849	0.8	0.4; 1.2	•	100	0.084
Metronidazole	10	3297	11.6	6.7 ; 16.5	•	100	0.711
Watch antibiotics							
Cefotaxime	12	8419	3.9	1.3;6.4	•	100	0.182
Ceftriaxone	14	9195	60.2	34.2;86.1		100	0.050
Cefixime	7	2664	13.8	0.0;29.8	-	100	NA
Cefoperazone	7	6542	8.1	4.3;11.9	•	100	NA
Meropenem	10	8494	10.4	6.0; 14.8	•	100	0.325
Azithromycin	4	1438	2.2	0.7;3.7	•	100	NA
Ciprofloxacin	15	5192197	5.5	4.9;6.0	•	100	0.415
Levofloxacin	12	8867	21.4	15.4 ; 27.3	•	100	0.944
Total	20	5193626	110.1	98.5 ; 121.6	_	100	0.047

The figure summarizes 20 reports in the domain antibiotic consumption, expressed as DDD/100 patient-days, for the top-15 antibiotics. Egger's tests to assess publication bias could only be performed for the primary analysis and the individual AWaRe antibiotics.

Abbreviations: CI, confidence interval; DDD, defined daily dose; NA, not applicable.

Figure 4. Summary forest plot on prescribing appropriateness

(A) Overall appropriateness of antibiotic prescribing based on Gyssens method (18 reports)



(B) Overall appropriateness of antibiotic prescribing based on reference guidelines (31 reports)

N	Events	Total	Proportion (%)	95% CI						P (%)	Egger's test p-value
9	1062	1069	99.8	98.0 ; 100.0						6.4	NA
16	3634	3882	99.6	95.2 ; 100.0					-	96.9	0.092
27	3647	6222	84.3	52.3;96.3			_		_	96.6	0.305
27	3767	5932	80.0	57.3 ; 92.3				•	-	97.7	0.732
13	1967	2431	94.2	59.3 ; 99.5				-	•	96.3	0.580
19	1946	3511	65.8	38.6 ; 85.5				•		94.6	0.074
9	1174	2007	100.0	97.2 ; 100.0					•	0.0	NA
6	265	1548	8.0	1.0;43.6	-	+	-,-		_	97.9	NA
	9 16 27 27 13 19	9 1062 16 3634 27 3647 27 3767 13 1967 19 1946 9 1174	9 1062 1069 16 3634 3882 27 3847 6222 27 3767 5932 13 1967 2431 19 1946 3511 9 1174 2007	9 1062 1069 99.8 16 3634 3882 99.6 27 3647 6222 84.3 27 3767 5932 80.0 13 1967 2431 94.2 19 1946 3511 65.8 9 1174 2007 100.0	9 1062 1069 99.8 98.0;100.0 16 3634 3882 99.6 95.2;100.0 27 3647 6222 84.3 52.3;96.3 27 3767 5932 80.0 57.3;92.3 13 1967 2431 94.2 59.3;99.5 19 1946 3511 65.8 38.6;85.5 9 1174 2007 100.0 97.2;100.0	9 1062 1069 99.8 98.0;100.0 16 3634 3882 99.6 95.2;100.0 27 3647 6222 84.3 52.3;96.3 27 3767 5932 80.0 57.3;92.3 13 1967 2431 94.2 59.3;99.5 19 1946 3511 65.8 38.6;85.5 9 1174 2007 100.0 97.2;100.0	9 1062 1069 99.8 98.0;100.0 16 3634 3882 99.6 95.2;100.0 27 3647 6222 84.3 52.3;96.3 27 3767 5932 80.0 57.3;92.3 13 1967 2431 94.2 59.3;99.5 19 1946 3511 65.8 38.6;85.5 9 1174 2007 100.0 97.2;100.0 6 265 1548 8.0 1.0;43.6	9 1062 1069 99.8 98.0;100.0 16 3634 3882 99.6 95.2;100.0 27 3647 6222 84.3 52.3;96.3	9 1062 1069 99.8 98.0;100.0 16 3634 3882 99.6 95.2;100.0 27 3647 6222 84.3 52.3;96.3 27 3767 5932 80.0 57.3;92.3 13 1967 2431 94.2 59.3;99.5 19 1946 3511 65.8 38.6;85.5 9 1174 2007 100.0 97.2;100.0 6 265 1548 8.0 1.0;43.6	9 1062 1069 99.8 98.0;100.0 16 3634 3882 99.6 95.2;100.0 27 3647 6222 84.3 52.3;96.3 27 3767 5932 80.0 57.3;92.3 13 1967 2431 94.2 59.3;99.5 19 1946 3511 65.8 38.6;85.5 9 1174 2007 100.0 97.2;100.0	9 1062 1069 99.8 98.0;100.0 16 3634 3882 99.6 95.2;100.0 27 3647 6222 84.3 52.3;96.3 28 3767 5932 80.0 57.3;92.3 39 1967 2431 94.2 59.3;99.5 39 1946 3511 65.8 38.6;85.5 9 1174 2007 100.0 97.2;100.0 6 265 1548 8.0 1.0;43.6

The figure summarizes 49 reports in the domain prescribing appropriateness based on Gyssens method (A) or references guidelines (B). Indicators (B) were reported by different numbers of studies. Egger's tests to assess publication bias in Gyssens method (A) could only be performed for the primary analysis. Abbreviations: CI, confidence interval; NA, not applicable.